DelveInsight’s Erectile Dysfunction market report overview of pathophysiology, various diagnostic approaches, and treatment algorithm, including detailed chapters for marketed products and emerging therapies
DelveInsight’s “Erectile Dysfunction Market Insights“ report delivers an in-depth understanding of the Erectile Dysfunction, historical and forecasted epidemiology, as well as the Erectile Dysfunction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) & Japan
Some of the key highlights from the Erectile Dysfunction market insights
- A more extensive national study, the National Health and Social Life Survey, looked at sexual function surveyed 1,410 men aged 18 to 59 and documented an increase in ED with age.
- Additionally, the study found a decrease in sexual desire with increasing age. Men in the oldest cohort (50 to 59) were more than three times as likely to experience erection problems and report low sexual desire as men 18 to 29.
- Experience of sexual dysfunction was more likely among men in poor physical and emotional health.
- Major players such as VIVUS, Eli Lily and Company, Bayer Pharmaceuticals Corporation, and others are involved in developing therapies for the treatment and management of Erectile Dysfunction. These therapies are currently under different stages of development.
- Key pipeline therapies in the Erectile Dysfunction market include Stendram (Stendra:), Cialis (Eli Lily and company), Levitra (Bayer Pharmaceuticals Corporation), MED2005 (Futura Medical), APC-8000 (Adamis Pharmaceuticals Corporation), and many others.
Request for sample for deep insights into ED Market @ Erectile Dysfunction Market Report
Erectile Dysfunction: Overview
Erectile dysfunction (ED) is a multidimensional but joint male sexual dysfunction marked by the incapability to evolve or maintain an erection of the penis during sexual activity. ED (also known as impotence) can have psychological consequences as it can be tied to relationship difficulties and self-image.
Erectile Dysfunction Epidemiology Segmentation
- Prevalent Cases of Erectile Dysfunction (ED) in 7MM [2017–2030]
- Diagnosed and Treatable Cases of Erectile Dysfunction (ED) in the 7MM [2017–2030]
- Age-Specific Prevalent Cases of Erectile Dysfunction (ED) in 7MM [2017–2030]
Visit here for more information @ Erectile Dysfunction Epidemiology Segmentation
Erectile dysfunction is the repeatedly reported medical condition in men. It does affect not only the individual but also causes strain on a couple’s lifestyle and relationship.
- PDE5 inhibitors (Sildenafil, Vardenafil, Tadalafil, and Avanafil)
- Vasodilators (Alprostadil, Papaverine, and Phentolamine)
- Androgens (Testosterone)
- (Majorly invasive therapies)
- Eli Lily and company
- Bayer Pharmaceuticals Corporation
- Futura Medical
- Adamis Pharmaceuticals Corporation
- Novartis Pharmaceuticals
- Urovant Sciences
- N4 Pharma
- 11 Years Forecast
- 7MM Coverage
- Erectile Dysfunction Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Erectile Dysfunction Key Questions Answered in the report
- What was the Erectile Dysfunction market share (%) distribution in 2017, and how it would look in 2030?
- What would be the Erectile Dysfunction market size and market size by therapies across the 7MM during the forecast period (2017-2030)?
- What are the key findings of the market across 7MM, and which country will have the largest Erectile Dysfunction market size during the forecast period (2017-2030)?
- At what CAGR, the Erectile Dysfunction market is expected to grow by 7MM during the forecast period (2017-2030)?
- What would be the Erectile Dysfunction market outlook across the 7MM during the forecast period (2017-2030)?
- What would be the Erectile Dysfunction market growth till 2030, and what will be the resultant market Size in the year 2030?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Please speak to our Experts @Erectile Dysfunction Market Report
List of Table of content
|2||Executive Summary of Erectile Dysfunction|
|3||Competitive Intelligence Analysis for Erectile Dysfunction|
|4||Erectile Dysfunction: Market Overview at a Glance|
|5||Erectile Dysfunction: Disease Background and Overview|
|7||Erectile Dysfunction Epidemiology and Patient Population|
|8||Treatment Algorithm, Current Treatment, and Medical Practices|
|10||Key Endpoints of Erectile Dysfunction Treatment|
|13||Erectile Dysfunction: Seven Major Market Analysis|
|15||7MM: Market Outlook|
|16||Access and Reimbursement Overview of Erectile Dysfunction|
Get to know about report @ Erectile Dysfunction Market Outlook
Erectile Dysfunction Devices Market Insights, Competitive Landscape and Market Forecast-2025 report delivers an in-depth understanding of Erectile Dysfunction Devices and the historical.
DelveInsight’s Erectile Dysfunction – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Erectile Dysfunction United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Erectile Dysfunction: Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020″ report by DelveInsight offers comprehensive insights on marketed and Phase III products for Erectile Dysfunction.
Erectile Dysfunction Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Erectile Dysfunction market.
Visit our blog-
- Prostate Cancer Market Experiences an Influx of the Pharma Players Veering the Market Ahead
- Top 5 Cancers Creating Major Challenge to the Global Healthcare System
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences providing comprehensive end-to-end solutions to improve performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Contact Us Shruti Thakur [email protected] +1(919)321-6187 www.delveinsight.com